Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 382086, 7 pages
http://dx.doi.org/10.1155/2015/382086
Review Article

Short-Term Effects of Verapamil and Diltiazem in the Treatment of No Reflow Phenomenon: A Meta-Analysis of Randomized Controlled Trials

Heart Center at Puai Hospital, Wuhan Puai Hospital, Huazhong University of Science and Technology, Wuhan 430030, China

Received 28 July 2015; Revised 28 August 2015; Accepted 31 August 2015

Academic Editor: Kai Hu

Copyright © 2015 Lan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Schofer, R. Montz, and D. G. Mathey, “Scintigraphic evidence of the ‘no reflow’ phenomenon in human beings after coronary thrombolysis,” Journal of the American College of Cardiology, vol. 5, no. 3, pp. 593–598, 1985. View at Publisher · View at Google Scholar · View at Scopus
  2. J. H. Chesebro, G. Knatterud, R. Roberts et al., “Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge,” Circulation, vol. 76, no. 1, pp. 142–154, 1987. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Kloner, C. E. Ganote, and R. B. Jennings, “The ‘no reflow’ phenomenon after temporary coronary occlusion in the dog,” The Journal of Clinical Investigation, vol. 54, no. 6, pp. 1496–1508, 1974. View at Publisher · View at Google Scholar · View at Scopus
  4. R. N. Piana, G. Y. Paik, M. Moscucci et al., “Incidence and treatment of ‘no-reflow’ after percutaneous coronary intervention,” Circulation, vol. 89, no. 6, pp. 2514–2518, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. K. M. Abbo, M. Dooris, S. Glazier et al., “Features and outcome of no-reflow after percutaneous coronary intervention,” The American Journal of Cardiology, vol. 75, no. 12, pp. 778–782, 1995. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. Kloner, “No-reflow phenomenon: maintaining vascular integrity,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 16, no. 3-4, pp. 244–250, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Ito, A. Maruyama, K. Iwakura et al., “Clinical implications of the ‘no reflow’ phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction,” Circulation, vol. 93, no. 2, pp. 223–228, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Ito and K. Iwakura, “Assessing the relation between coronary reflow and myocardial reflow,” The American Journal of Cardiology, vol. 81, no. 12, supplement 1, pp. 8G–12G, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. M. A. Chaudhry, M. Smith, E. B. Hanna, and R. Lazzara, “Diverse spectrum of presentation of coronary slow flow phenomenon: a concise review of the literature,” Cardiology Research and Practice, vol. 2012, Article ID 383181, 6 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Berg and C. Buhari, “Treating and preventing no reflow in the cardiac catheterization laboratory,” Current Cardiology Reviews, vol. 8, no. 3, pp. 209–214, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. G. N. Levine, E. R. Bates, J. C. Blankenship et al., “2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions,” Journal of the American College of Cardiology, vol. 58, pp. e44–e122, 2011. View at Google Scholar
  12. R. M. Pomerantz, R. E. Kuntz, D. J. Diver, R. D. Safian, and D. S. Baim, “Intracoronary verapamil for the treatment of distal microvascular coronary artery spasm following PTCA,” Catheterization and Cardiovascular Diagnosis, vol. 24, no. 4, pp. 283–285, 1991. View at Publisher · View at Google Scholar · View at Scopus
  13. F. J. Weyrens, J. Mooney, J. Lesser, and M. R. Mooney, “Intracoronary diltiazem for microvascular spasm after interventional therapy,” The American Journal of Cardiology, vol. 75, no. 12, pp. 849–850, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Jalinous, J. A. Mooney, and M. R. Mooney, “Pretreatment with intracoronary diltiazem reduces non-q-wave myocardial infarction following directional atherectomy,” The Journal of Invasive Cardiology, vol. 9, no. 4, pp. 270–273, 1997. View at Google Scholar · View at Scopus
  15. K. Saito, H. Nonogi, Y. Goto et al., “Antiischemic effect of intracoronary diltiazem on myocardial ischemia during PTCA,” Heart and Vessels, vol. 11, no. 2, pp. 92–99, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Taniyama, H. Ito, K. Iwakura et al., “Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction,” Journal of the American College of Cardiology, vol. 30, no. 5, pp. 1193–1199, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. Q. Su, L. Li, and Y. Liu, “Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials,” Clinical Cardiology, vol. 36, no. 8, pp. E11–E16, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. Q. Su, T. S. Nyi, and L. Li, “Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction,” Cochrane Database of Systematic Reviews, vol. 5, Article ID CD009503, 2015. View at Publisher · View at Google Scholar
  19. K. Vijayalakshmi, V. J. Whittaker, B. Kunadian et al., “Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes,” Heart, vol. 92, no. 9, pp. 1278–1284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Hendler, A. Aronovich, E. Kaluski et al., “Optimization of myocardial perfusion after primary coronary angioplasty following an acute myocardial infarction. Beyond TIMI 3 flow,” The Journal of Invasive Cardiology, vol. 18, no. 1, pp. 32–36, 2006. View at Google Scholar · View at Scopus
  21. S.-F. Chang, J.-Y. Ma, J.-Y. Qian, X.-H. Shu, and J.-B. Ge, “Effects of intracoronary administration of nitroglycerin and verapamil for treatment of coronary slow flow phenomenon,” Zhonghua Xin Xue Guan Bing Za Zhi, vol. 38, no. 1, pp. 27–30, 2010. View at Google Scholar · View at Scopus
  22. D. Huang, J. Qian, L. Ge et al., “REstoration of COronary flow in patients with no-reflow after primary coronary interVEntion of acute myocaRdial infarction (RECOVER),” American Heart Journal, vol. 164, no. 3, pp. 394–401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Li, Y. Gu, T. Liu et al., “A randomized, single-center double-blinded trial on the effects of diltiazem sustained-release capsules in patients with coronary slow flow phenomenon at 6-month follow-up,” PLoS ONE, vol. 7, no. 6, Article ID e38851, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. I. Ozdogru, C. Zencir, A. Dogan et al., “Acute effects of intracoronary nitroglycerin and diltiazem in coronary slow flow phenomenon,” Journal of Investigative Medicine, vol. 61, no. 1, pp. 45–49, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. I. F. Akturk, A. A. Yalcin, I. Biyik et al., “Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction,” Minerva Cardioangiologica, vol. 62, pp. 389–397, 2014. View at Google Scholar
  26. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Salinas, S. Jimenez-Valero, R. Moreno et al., “Update in pharmacological management of coronary no-reflow phenomenon,” Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 10, no. 3, pp. 256–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. W. J. Elliott and C. V. S. Ram, “Calcium channel blockers,” Journal of Clinical Hypertension, vol. 13, no. 9, pp. 687–689, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Soukoulis, W. E. Boden, S. C. Smith, and P. T. O'Gara, “Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon,” Circulation Research, vol. 114, no. 12, pp. 1944–1958, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Reffelmann and R. A. Kloner, “The ‘no-reflow’ phenomenon: basic science and clinical correlates,” Heart, vol. 87, no. 2, pp. 162–168, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Galiuto, “Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification,” Heart, vol. 90, no. 2, pp. 123–125, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. J.-L. Zhao, Y.-J. Yang, C.-J. Cui, S.-J. You, Y.-J. Wu, and R.-L. Gao, “Different effects of adenosine and calcium channel blockade on myocardial no-reflow after acute myocardial infarction and reperfusion,” Cardiovascular Drugs and Therapy, vol. 20, no. 3, pp. 167–175, 2006. View at Publisher · View at Google Scholar · View at Scopus